FIELD: medicine.
SUBSTANCE: what is presented is an antibody neutralising endothelial cell infection by human cytomegalovirus (hCMV) characterised by the presence of three heavy chain CDR and three light-chain CDR. There are described: a nucleic acid for antibody expression containing coding NA and a cell based on such expressing NA. There are disclosed: a composition for preventing and treating hCMV based on the antibody and the use of the antibody or NA for preparing a drug for treating hCMV. The invention provides the antibodies the concentration of which are required for 50% neutralisation of hCMV in endothelial cells makes 0.003 mcg/ml or less that can find further application in methods of screening, as well as in diagnosing and treating the hCMV-mediated diseases.
EFFECT: higher effectiveness of the use of the antibodies.
13 cl, 5 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MONOCLONAL ANTIBODY ABLE TO BIND TO SPECIFIC DISCONTINUOUS EPITOPE PLACED IN AD1 REGION OF HUMAN CYTOMEGALOVIRUS GB GLYCOPROTEIN, AND ITS ANTIGEN-BINDING FRAGMENT | 2010 |
|
RU2542472C2 |
| HUMAN CYTOMEGALOVIRUS ANTIBODY AND USE THEREOF | 2020 |
|
RU2817217C1 |
| ANTIBODY OR FRAGMENT THEREOF WITH HIV-NEUTRALISING ACTIVITY | 2005 |
|
RU2380378C2 |
| NOVEL ANTI-IL13 ANTIBODIES AND USE THEREOF | 2004 |
|
RU2487887C2 |
| ANTIBODIES OF DOGS WITH MODIFIED CH2-CH3 SEQUENCES | 2014 |
|
RU2687209C1 |
| NEUTRALISING ANTI-INFLUENZA A VIRUS ANTIBODIES AND USING THEM | 2009 |
|
RU2553325C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| HUMAN INTERLEUKIN 17 (IL-17) ANTIBODIES AND USING THEM | 2009 |
|
RU2539029C2 |
| EXPRESSION VECTOR ELEMENT COMBINATION, NEW METHODS FOR OBTAINING PRODUCER CELLS AND THEIR APPLICATION FOR RECOMBINANT PRODUCTION OF POLYPEPTIDES | 2012 |
|
RU2639519C2 |
| METHODS OF COMBINED THERAPY USING BINDING MATERIALS WITH PSL AND PCRV PSEUDOMONAS | 2012 |
|
RU2687588C2 |
